Patient passed away [death].Case (b)(4) is a serious spontaneous case received from the patient's daughter via a regulatory authority in united states.This report concerns a patient (patient identifiers were not provided) who patient passed away during treatment with intra-articular euflexxa (sodium hyaluronate) solution for injection 10mg/ml, unknown dose and frequency, used for unknown indication from an unknown start date to an unknown stop date.The patient's daughter reported that the patient passed away on (b)(6) 2021.Only filled 2020.Action taken with euflexxa was not applicable.At the time of the report, the outcome of patient passed away was fatal.No concomitant medication was reported.All events in the case were reported as serious.At the time of reporting the case outcome was fatal.Overall listedness (core label) is unlisted.Reporter causality: related, company causality: not related.Sender´s comment: based on the known safety profile, when used according to label, it is considered highly unlikely that euflexxa caused the patient's death.Company causality not related.Other case numbers: internal # others = mw5104438.This ae occurred in united states and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it does not meet the definition of a medical device incident according to the requirements of the medical device directive/ because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer.No corrective action was done by the manufacturer or requested by regulators.
|